Remibrutinib
Sign in to save this workspacePrimary targets: BTK · FDA status: FDA Phase III Trials
Selectivity scorecard
KISS
99.50
Gini
0.721
CATDS
0.076
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Remibrutinib. Strongest target: BTK at 97.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | BTK | 97.7% | 2.3% |
| 2 | BMX_ETK | 91.9% | 8.1% |
| 3 | TEC | 71.9% | 28.1% |
| 4 | SGK2 | 22.5% | 77.5% |
| 5 | PKN3_PRK3 | 20.1% | 79.9% |
| 6 | TYK2 | 16.2% | 83.8% |
| 7 | P38D_MAPK13 | 14.9% | 85.1% |
| 8 | MST4 | 13.7% | 86.3% |
| 9 | LCK2_ICK | 13.1% | 86.9% |
| 10 | ROCK1 | 13.1% | 86.9% |
| 11 | IKKE_IKBKE | 12.8% | 87.2% |
| 12 | NEK3 | 12.3% | 87.7% |
| 13 | TXK | 11.8% | 88.2% |
| 14 | PKG1B | 11.0% | 89.0% |
| 15 | WNK3 | 10.6% | 89.4% |
| 16 | RIPK2 | 10.5% | 89.5% |
| 17 | CDK2_CYCLIN_A1 | 10.5% | 89.5% |
| 18 | CAMKK1 | 10.3% | 89.8% |
| 19 | PAK6 | 10.2% | 89.8% |
| 20 | MKK6 | 10.1% | 89.9% |
Selectivity landscape
Where Remibrutinib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Remibrutinib.
Atlas insights for Remibrutinib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target19%
Off-target81%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 280.32 | |
| ALLOGRAFT_REJECTION | 986.85 | |
| ANDROGEN_RESPONSE | 323.29 | |
| ANGIOGENESIS | 80.14 | |
| APICAL_JUNCTION | 850.63 | |
| APICAL_SURFACE | 68.44 | |
| APOPTOSIS | 796.09 | |
| BILE_ACID_METABOLISM | 80.64 | |
| CHOLESTEROL_HOMEOSTASIS | 67.55 | |
| COAGULATION | 90.62 | |
| COMPLEMENT | 471.77 | |
| DNA_REPAIR | 415.55 | |
| E2F_TARGETS | 687.36 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 424.92 | |
| ESTROGEN_RESPONSE_EARLY | 355.48 | |
| ESTROGEN_RESPONSE_LATE | 329.07 | |
| FATTY_ACID_METABOLISM | 36.26 | |
| G2M_CHECKPOINT | 694.36 | |
| GLYCOLYSIS | 244.39 | |
| HEDGEHOG_SIGNALING | 94.48 | |
| HEME_METABOLISM | 273.03 | |
| HYPOXIA | 477.40 | |
| IL2_STAT5_SIGNALING | 370.68 | |
| IL6_JAK_STAT3_SIGNALING | 341.44 | |
| INFLAMMATORY_RESPONSE | 679.26 | |
| INTERFERON_ALPHA_RESPONSE | 83.92 | |
| INTERFERON_GAMMA_RESPONSE | 532.17 | |
| KRAS_SIGNALING_DN | 106.27 | |
| KRAS_SIGNALING_UP | 354.57 | |
| MITOTIC_SPINDLE | 855.29 | |
| MTORC1_SIGNALING | 469.54 | |
| MYC_TARGETS_V1 | 380.77 | |
| MYC_TARGETS_V2 | 132.76 | |
| MYOGENESIS | 628.49 | |
| NOTCH_SIGNALING | 35.90 | |
| OXIDATIVE_PHOSPHORYLATION | 76.14 | |
| P53_PATHWAY | 576.89 | |
| PANCREAS_BETA_CELLS | 70.76 | |
| PEROXISOME | 107.12 | |
| PI3K_AKT_MTOR_SIGNALING | 1114.25 | |
| PROTEIN_SECRETION | 161.43 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 48.29 | |
| SPERMATOGENESIS | 175.20 | |
| TGF_BETA_SIGNALING | 295.58 | |
| TNFA_SIGNALING_VIA_NFKB | 695.48 | |
| UNFOLDED_PROTEIN_RESPONSE | 170.65 | |
| UV_RESPONSE_DN | 466.57 | |
| UV_RESPONSE_UP | 400.27 | |
| WNT_BETA_CATENIN_SIGNALING | 369.15 | |
| XENOBIOTIC_METABOLISM | 241.38 |
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| TCGA-CF-A5U8-01A-11R-A28M-07 | — | 0.845 |
| EPT0291 | EPN | 0.844 |
| SRR1443713 | GTEX | 0.824 |
| SRR10899984 | — | 0.819 |
| SRR12202498 | — | 0.818 |
Annotations
Sign in to read and post annotations.
Loading…